Compare ON Semiconductor (ON) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ON Semiconductor vs Repligen Corporation Common Stock — how do they compare? ON Semiconductor trades at $72.9 (market cap $29.86B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: ON Semiconductor is far larger — about 2.7× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, ON Semiconductor nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ON Semiconductor for 7 Days and Repligen Corporation Common Stock for 0 Days on average.
| ON | RGEN | |
|---|---|---|
Market Cap | $29.86B | $11.14B |
Volume | 7,140,901 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $133.93 | $194.57 |
52-Week Low | $44.90 | $102.87 |
Typical Hold Time | 7 Days | 0 Days |
Enterprise Value | $30.48B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ON Semiconductor (ON) trades at $76.69, up 0.91% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company reported strong Q2 2026 results with 9% revenue growth and significant EPS expansion, while analyst consensus remains positive with a $100 price target. Recent news highlights the revised Synaptics acquisition and AI infrastructure opportunities.
The stock presents a turnaround story with improving profitability and AI growth potential, though technical weakness and competitive pressures warrant caution. Upside catalysts include margin expansion and data center demand, while risks include integration challenges from the Synaptics deal and semiconductor cycle volatility.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ON Semiconductor
Onsemi develops power and sensing semiconductors for automotive, industrial, and energy applications. Its products support functions such as electric vehicle systems, energy conversion, automation, and intelligent sensing.
Read more on ON →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
